<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Improved survival of <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> has been made over the last 3 decades; reasons may be attributed to early detection through screening, and better treatment options </plain></SENT>
<SENT sid="1" pm="."><plain>Advancements in modern systemic chemotherapy for <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> include <z:chebi fb="0" ids="31941">oxaliplatin</z:chebi>-based and irinotecan-based combination and the introduction of biological agents such as bevacizumab and cetuximab </plain></SENT>
<SENT sid="2" pm="."><plain>Systemic therapies need to be used in patients with high risk stage II and <z:e sem="disease" ids="C0677949" disease_type="Neoplastic Process" abbrv="">stage III colorectal cancer</z:e> and in patients with <z:e sem="disease" ids="C0027627" disease_type="Neoplastic Process" abbrv="mets">metastatic disease</z:e> </plain></SENT>
<SENT sid="3" pm="."><plain>Evidence for liver resection and ablation, pulmonary metastasectomy and/or radiofrequency ablation, and cytoreductive surgery combined with hyperthermic intraperitoneal chemotherapy for <z:e sem="disease" ids="C0027627" disease_type="Neoplastic Process" abbrv="mets">metastasis</z:e> to sites of the liver, lung, and peritoneum respectively are well established </plain></SENT>
<SENT sid="4" pm="."><plain>The biggest challenge is to select the right patients for metastasectomy and to pursue <z:e sem="disease" ids="C0027627" disease_type="Neoplastic Process" abbrv="mets">metastatic disease</z:e> as a <z:hpo ids='HP_0011010'>chronic</z:hpo> disease to ensure appropriate personalized therapy, pursue second-line therapies or repeat surgeries, and minimize toxicities of therapies </plain></SENT>
</text></document>